Skip to content
Screener

Citius Oncology, Inc. CTOR Total Revenue

Total Revenue at other companies

Merck & Co. logo
Merck & Co.MRK
$16.61B+5.1%
Delcath Systems logo
Delcath SystemsDCTH
$29.13M+20.6%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$99.31M+65.7%
Immunome logo
ImmunomeIMNM
$0-100%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$41M-74.4%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$44.21M+168%

Other financials

Income statement

See full
Gross profit$1.0M—
Operating income-$8.7M-76.3%
Net income-$8.9M-66.2%
EPS (diluted)-$0.080.0%

Balance sheet

See full
Cash & equivalents$16.6M+14,788,922%
Total debt$16.4M—
Total equity$40.4M+24.7%
Total assets$112.1M+22.2%

Cash flow

See full
Operating cash flow-$2.7M-97.4%

Valuation

See full
Market cap$83.24M-49.2%
Enterprise value$83.09M—

Returns & leverage

See full
Return on equity-126.6%+27.2pp
Debt / equity0.4×—
Current ratio0.7×+0.4×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: Citius Oncology, Inc.’s 10-Q, filed August 14, 2026. Open the filing →

Filed
Aug 14, 2026, 4:35 PM EDT
Fiscal quarter
Q3 FY2026
Calendar quarter
Q2 2026
Accession
0001213900-26-090184

FAQ

What is Citius Oncology, Inc.'s total revenue?
Citius Oncology, Inc. (CTOR) reported total revenue of $1.49M in Q2 2026.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Ask your AI about Citius Oncology, Inc.'s total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude